Study #2024-0210
A phase 2 clinical trial evaluating the efficacy and safety of dual immune checkpoint inhibition with anti-PD-L1 (atezolizumab) and anti-TIGIT (tiragolumab) in cancer of unknown primary
MD Anderson Study Status
Not Accepting
Treatment Agent
Atezolizumab, Tiragolumab
Description
The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cancer
Study phase:
Phase II
Physician name:
Ryan Huey
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.